PE20080891A1 - Anticuerpos anti-notch3 y composiciones que los comprenden - Google Patents

Anticuerpos anti-notch3 y composiciones que los comprenden

Info

Publication number
PE20080891A1
PE20080891A1 PE2007001413A PE2007001413A PE20080891A1 PE 20080891 A1 PE20080891 A1 PE 20080891A1 PE 2007001413 A PE2007001413 A PE 2007001413A PE 2007001413 A PE2007001413 A PE 2007001413A PE 20080891 A1 PE20080891 A1 PE 20080891A1
Authority
PE
Peru
Prior art keywords
antibody
compositions
identity
refers
detection
Prior art date
Application number
PE2007001413A
Other languages
English (en)
Inventor
Kang Li
Sek Chung Fung
Zhengbin Yao
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PE20080891A1 publication Critical patent/PE20080891A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE REFIERE A UN ANTICUERPO O FRAGMENTO DE ANTICUERPO QUE COMPRENDE: A) UNA REGION VARIABLE DE LA CADENA LIGERA CON 95% DE IDENTIDAD CON LAS SECUENCIAS SEQ ID NO: 3, 5, 7, 11, 12, 13, ENTRE OTROS, EL CUAL TIENE UN PEPTIDO SENAL; Y B) UNA REGION VARIABLE DE LA CADENA PESADA CON 95% DE IDENTIDAD CON LAS SECUENCIAS SEQ ID NO: 2, 4, 6, 8, 9, 10, ENTRE OTROS, EL CUAL CONTIENE LOS DOMINIOS CH1, CH2 Y CH3 DE UNA REGION CONSTANTE QUE ES UN ANTICUERPO IgG1, IgG2, IgG3 O IgG4. SE REFIERE TAMBIEN A UNA COMPOSICION QUE COMPRENDE EL ANTICUERPO Y A UN KIT DE DETECCION O PURIFICACION DEL GEN NOTCH3. DICHO ANTICUERPO SE UNE ESPECIFICAMENTE AL GEN NOTCH3 SIENDO UTIL EN LA DETECCION Y DIAGNOSTICO DE CANCER
PE2007001413A 2006-10-19 2007-10-18 Anticuerpos anti-notch3 y composiciones que los comprenden PE20080891A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85286106P 2006-10-19 2006-10-19

Publications (1)

Publication Number Publication Date
PE20080891A1 true PE20080891A1 (es) 2008-08-25

Family

ID=39745392

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001413A PE20080891A1 (es) 2006-10-19 2007-10-18 Anticuerpos anti-notch3 y composiciones que los comprenden

Country Status (11)

Country Link
US (2) US8513388B2 (es)
EP (1) EP2081962B1 (es)
CN (1) CN101563366B (es)
AR (1) AR063493A1 (es)
CA (1) CA2666179A1 (es)
CL (1) CL2007002989A1 (es)
PE (1) PE20080891A1 (es)
TW (1) TW200823293A (es)
UA (1) UA102061C2 (es)
WO (1) WO2008136848A2 (es)
ZA (1) ZA200902419B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007145840A2 (en) 2006-06-13 2007-12-21 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
TW200824707A (en) 2006-10-19 2008-06-16 Genentech Inc Anti-Notch3 agonist antibodies and their use in the treatment of Notch3-related diseases
AR064388A1 (es) * 2006-12-18 2009-04-01 Genentech Inc Anticuerpos antagonistas anti- notch3 y su uso en la prevencion y el tratamiento de enfermedades relacionadas con el receptor notch3
CA2676008A1 (en) 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
MX2011000233A (es) 2008-07-08 2011-05-19 Oncomed Pharm Inc Agentes de union del receptor notch1 y metodos para su uso.
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
RU2012117619A (ru) * 2009-09-30 2013-11-10 Дженентек, Инк. ЛЕЧЕНИЕ ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ, УСТОЙЧИВЫХ К ДЕЙСТВИЮ АНТАГОНИСТА Notch1, С ПОМОЩЬЮ АНТАГОНИСТА Notch3
EP2523682B1 (en) 2010-01-13 2015-12-16 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
US9228022B2 (en) 2010-06-30 2016-01-05 Novo Nordisk A/S Antibodies that are capable of specifically binding tissue factor pathway inhibitor
US9260518B2 (en) 2010-06-30 2016-02-16 Novo Nordisk A/S Antibodies that are capable of specifically binding tissue factor pathway inhibitor
EP2917240A1 (en) 2012-11-07 2015-09-16 Pfizer Inc. Anti-notch3 antibodies and antibody-drug conjugates
JP2016514130A (ja) * 2013-03-14 2016-05-19 ノバルティス アーゲー Ｎｏｔｃｈ３に対する抗体
JP2017526641A (ja) 2014-07-11 2017-09-14 ジェネンテック， インコーポレイテッド Ｎｏｔｃｈ経路阻害
WO2020047099A1 (en) 2018-08-28 2020-03-05 Fred Hutchinson Cancer Research Center Methods and compositions for adoptive t cell therapy incorporating induced notch signaling
CN111979162B (zh) * 2019-05-22 2024-02-13 上海市公共卫生临床中心 重组卡介苗菌株、其制备方法和用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE20030749A1 (en) 1991-05-03 2003-11-12 Indiana University Foundation Human notch and delta binding domains in torporythmic proteins, and methods based thereon
US20050112121A1 (en) 1992-04-30 2005-05-26 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US5786158A (en) 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
EP0733070A1 (en) * 1993-12-08 1996-09-25 Genzyme Corporation Process for generating specific antibodies
US20050158859A1 (en) 1995-09-29 2005-07-21 Yale University Manipulation of non-terminally differentiated cells using the Notch pathway
US5780300A (en) 1995-09-29 1998-07-14 Yale University Manipulation of non-terminally differentiated cells using the notch pathway
FR2751986B1 (fr) * 1996-08-01 1998-12-31 Inst Nat Sante Rech Med Gene implique dans le cadasil, methode de diagnostic et application therapeutique
US6692919B1 (en) 1997-07-23 2004-02-17 Yale University Activated forms of notch and methods based thereon
US6436650B1 (en) 1997-07-23 2002-08-20 Yale University Activated forms of notch and methods based thereon
FR2777285B1 (fr) 1998-04-10 2000-05-19 Bio Merieux Ligand peptidique presentant une affinite specifique vis-a-vis de la proteine p24 du retrovirus hiv-1
WO2000020576A2 (en) * 1998-10-02 2000-04-13 The Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services, The National Institutes Of Health Methods and compositions for inducing differentiation and apotosis in cells that overexpess the notch protein
US8084258B2 (en) 1999-07-12 2011-12-27 University Of Basel Manipulation of tissue of organ type using the notch pathway
WO2002018544A2 (en) 2000-08-31 2002-03-07 Loyola University Chicago Method and reagents for treatment of skin disorders by modulating the notch pathway
EP1318830B1 (en) 2000-09-22 2012-10-24 Genentech, Inc. Constitutively active form of notch1 receptor or an anti-notch1 receptor antibody for the treatment of prostate cancer
AU2002339157A1 (en) * 2001-11-14 2003-05-26 Lorantis Limited Inhibitors of the notch signalling pathway for use in the treatment of cancer
EP1525221A1 (en) * 2002-08-03 2005-04-27 Lorantis Limited Conjugate of notch signalling pathway modulators and their use in medical treatment
CA2527863A1 (en) * 2003-06-02 2004-12-23 Alexion Pharmaceuticals, Inc. Cell surface protein associated with human chronic lymphocytic leukemia
US7837993B2 (en) * 2004-03-19 2010-11-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for regeneration of aged skeletal muscle tissues
AU2005271892A1 (en) * 2004-07-10 2006-02-16 Alexion Pharmaceuticals, Inc. Methods for discovering antibodies specific to cancer cells and antibodies discovered thereby
US7888116B2 (en) * 2004-07-22 2011-02-15 The United States Of America As Represented By The Department Of Health And Human Services Uses of notch receptors, notch ligands, and notch modulators in methods related to metabolic diseases
US20070077245A1 (en) 2004-08-04 2007-04-05 The Brigham And Women's Hospital, Inc. NOTCH mutations leading to increased receptor signaling
WO2006053063A2 (en) 2004-11-05 2006-05-18 The Regents Of The University Of California Notch-1 assay to detect neurodegenerative diseases
WO2006068822A1 (en) 2004-12-20 2006-06-29 Genentech, Inc. Notch receptor agonists and uses
AU2006326417B2 (en) 2005-12-16 2012-05-24 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with Dll4 antagonists
WO2008057144A2 (en) 2006-05-15 2008-05-15 The Brigham And Women's Hospital, Inc. Functional negative regulatory domain sequences from human notch1 and 2 and isolated lnr domains from human notch1
TW200824707A (en) 2006-10-19 2008-06-16 Genentech Inc Anti-Notch3 agonist antibodies and their use in the treatment of Notch3-related diseases
AR064388A1 (es) 2006-12-18 2009-04-01 Genentech Inc Anticuerpos antagonistas anti- notch3 y su uso en la prevencion y el tratamiento de enfermedades relacionadas con el receptor notch3
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica

Also Published As

Publication number Publication date
EP2081962A2 (en) 2009-07-29
WO2008136848A3 (en) 2009-02-26
AR063493A1 (es) 2009-01-28
CA2666179A1 (en) 2008-11-13
CL2007002989A1 (es) 2008-05-16
WO2008136848A2 (en) 2008-11-13
TW200823293A (en) 2008-06-01
US20140057288A1 (en) 2014-02-27
US20120142899A1 (en) 2012-06-07
EP2081962B1 (en) 2018-10-03
CN101563366B (zh) 2012-10-03
ZA200902419B (en) 2010-07-28
WO2008136848A4 (en) 2009-04-16
UA102061C2 (ru) 2013-06-10
US8513388B2 (en) 2013-08-20
CN101563366A (zh) 2009-10-21
US8956811B2 (en) 2015-02-17

Similar Documents

Publication Publication Date Title
PE20080891A1 (es) Anticuerpos anti-notch3 y composiciones que los comprenden
PE20081399A1 (es) Anticuerpos antagonistas anti-notch3 y su uso en la prevencion y el tratamiento de enfermedades relacionadas con el receptor notch3
PE20061323A1 (es) Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
PE20081264A1 (es) Anticuerpos agonistas anti-notch3
PE20141787A1 (es) Composiciones anti-cgrp y uso de las mismas
PE20140806A1 (es) Anticuerpos anti-factor d humanizados y sus usos
ES2547463T3 (es) Moléculas de unión a ILT3 y usos de las mismas
PE20140231A1 (es) Proteinas de union a antigeno contra proproteina converstasa subtilisina/kexina tipo 9 (pcsk9)
PE20110668A1 (es) Anticuerpos anti-linfopoyetina estromal timica (anti-tslp)
PE20120079A1 (es) Moleculas de anticuerpos mejoradas
GT200900167A (es) Anticuerpos humanos contra el ligando 4 de tipo delta humano.
PE20070374A1 (es) ANTICUERPOS ANTI-MAdCAM
PE20080846A1 (es) Composiciones y metodos relacionados con los anticuerpos receptores de glucagon
ECSP066710A (es) Mutantes de anticuerpo anti-cd40
PE20120205A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y citarabina
PE20121552A1 (es) Anticuerpos monoclonales anti cea humanizados de afinidad madura
PE20110382A1 (es) Tratamiento de enfermedad autoinmunitaria e inflamatoria
EA200800812A1 (ru) Композиции антитела против cd3
ES2572177T3 (es) Anticuerpos neutralizantes anti-B7RP1 humanos
PE20080035A1 (es) Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina
PE20080111A1 (es) Anticuerpos contra la il-22 humana y usos para los mismos
PE20140218A1 (es) Composicion farmaceutica
CO6231009A2 (es) Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes
CR9975A (es) Anticuerpos antagonistas dirigidos contra el péptido relacionado con el gen de calcitonina
PE20120427A1 (es) Anticuerpos contra el receptor de cgrp humano

Legal Events

Date Code Title Description
FA Abandonment or withdrawal